Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04106830

Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)

Sponsor: Beijing Tiantan Hospital

View on ClinicalTrials.gov

Summary

CLUE is a prospective study to determine structural and functional changes of brain and spinal cord, as well as the inflammatory environment in patients with neuroinflammatory and demyelination disease. Participants will receive new magnetic resonance (MR) technics including double inversion recovery (DIR) imaging diffusion kurtosis imaging (DKI), quantitative susceptibility mapping (QSM) and resting-state functional imaging and follow up for one year using 3T MRI. In addition, participants will receive T1WI, T2WI, FLAIR and SWI sequences on 7T MRI.

Official title: Prospective Cohort Study of CLinical and Imaging Patterns of NeUroinflammation DisEases (CLUE)

Key Details

Gender

All

Age Range

16 Years - 75 Years

Study Type

OBSERVATIONAL

Enrollment

1000

Start Date

2019-01-01

Completion Date

2028-12-31

Last Updated

2024-12-24

Healthy Volunteers

Yes

Interventions

DRUG

Intravenous steroid

This study does not limit treatment methods.patients commonly use high-dose intravenous steroid therapy (HD-S) during acute stage. The HD-S treatment course referred to intravenous administration of 1 g of glucocorticoid daily for 3 consecutive days and continuous dose 240 mg reduction for 60mg oral administration. Immunomodulatory therapies are necessary for the remission stage. The treatment methods include: Azathioprine (start at 50 mg per day, add 50 mg per week to 2 mg/kg.d); Mycophenolate Mofetil (The initial dose was 0.25g bid, add 0.5g per week to 0.75g bid); and Rituximab (500 mg on the 1st day, the 15th day, then 500mg per half year).

Locations (1)

Beijing Tiantan Hospital

Beijing, Beijing Municipality, China